Aquestive Therapeutics Announces Second Quarter Financial Results
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is set to report its financial results for the second quarter ending June 30. This announcement will take place after the market closes on August 11. As a leading pharmaceutical company focused on creating innovative delivery technologies that enhance patient care, Aquestive continues to make significant strides in its portfolio of orally administered medications.
Management Conference Call Scheduled
Following the financial results, management will host a conference call for investors on August 12 at 8:00 a.m. ET. This event presents an excellent opportunity for stakeholders to engage directly with the team and gain insights into the company’s recent developments and strategies moving forward.
Participation and Updates
Investors interested in participating in the call should register in advance to receive local or toll-free phone numbers along with a personal PIN. The dial-in number will be provided upon registration. Additionally, a live webcast of the conference call will be accessible through the Investors section on the Aquestive website.
Webcast Access and Archiving
For those who cannot attend the live call, a replay of the webcast will be available on the Investors section of the company's website. This replay will be archived for 30 days, ensuring that all interested parties can catch up on any missed information regarding Aquestive's performance and future prospects.
About Aquestive Therapeutics
Aquestive Therapeutics is dedicated to advancing pharmaceutical products designed to bring meaningful improvements to patients' lives. The company’s unique approach focuses on orally administered products, which provide new options for patients who typically rely on more invasive or inconvenient therapies. As the exclusive manufacturer of several licensed products marketed globally, Aquestive is positioned at the forefront of innovative drug development.
Product Portfolio and Collaborations
Aquestive's portfolio includes four commercialized products already on the market and a pipeline of proprietary candidates. Among these candidates are late-stage treatments for severe allergic reactions and an innovative topical gel for various dermatological conditions. The company collaborates with other pharmaceutical firms to push new molecules through the development cycle using their best-in-class technologies, including the patented PharmFilm®.
Forward-Looking Statements
As part of their reporting, Aquestive may share future projections based on current expectations. However, these statements are subject to uncertainties and risks that may cause actual outcomes to differ considerably. Investors are encouraged to consider these factors and remain informed through official updates.
Contact Information
For further inquiries, investors can reach out to Brian Korb at Astr Partners via email at Brian.korb@astrpartners.com. The company encourages any questions related to its financial reporting and performance strategies, reflecting their commitment to transparency and engagement with stakeholders.
Frequently Asked Questions
What is the date of Aquestive's second quarter financial results?
Aquestive Therapeutics will report its second quarter financial results on August 11.
When will the management conference call take place?
The conference call is scheduled for August 12 at 8:00 a.m. ET.
How can investors participate in the call?
Investors need to register in advance to receive call instructions, including the phone numbers and personal PINs.
Where can I access the live webcast of the conference call?
The live webcast can be accessed on the Investors section of the Aquestive Therapeutics website.
Are there any new product developments from Aquestive?
Aquestive is also advancing a late-stage proprietary candidate that addresses severe allergic reactions and an innovative topical gel for dermatology conditions.
